On November 21, 1997, the President
signed FDAMA (Pub. L. 105-115) into law. As one of its provisions,
FDAMA added section 515(d)(6) to the Act (21 U.S.C. 360e(d)(6)).
This new section provides that PMA supplements are required for all
changes that affect safety and effectiveness unless such changes
involve modifications to manufacturing procedures or method of
manufacture. Those types of manufacturing changes will require a
30-day notice or, where FDA finds such notice inadequate, a 135-day
PMA supplement. Examples of changes that potentially qualify for a
30-day notice are intended by the....
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.